What was the amount and timeframe of Swiss corporate investment in the U.S. reported by NZZ am Sonntag, and what agreement prompted this surge?

Swiss companies invested $27 billion in the United States between January and April, as part of Switzerland’s pledge to sharply increase investment following a tariff agreement with Washington; this pledge—announced on November 14—commits Swiss firms to invest $200 billion in the U.S. over five years, in exchange for the U.S. reducing punitive tariffs on Swiss goods from 39% to 15%.

Which major Swiss companies are cited in the report as making specific U.S. investments, and what types of projects are they undertaking?

Novartis announced two U.S. projects: a biomedical research centre in San Diego and a cancer-drug production facility in Texas; Roche is expanding output in North Carolina; medical technology company Ypsomed is building a new factory in North Carolina; shipping group MSC is establishing a new North American headquarters in Miami, including spending on cruise and logistics operations; and industrial firms Pfiffner Group and Elma are expanding U.S. production capacity.

Swiss Firms Invest $27 Billion in US After Tariff Deal, NZZ am Sonntag Reports

Jun 7, 2026

Swiss companies invested $27 billion in the U.S. between January and April following a tariff agreement reducing duties on Swiss goods. Major pharmaceutical firms Novartis and Roche announced new facilities, including a cancer-drug production plant in Texas.

reuters

2026-06-07

Swiss Firms Invest $27 Billion in US After Tariff Deal, NZZ am Sonntag Reports

2026-06-26

Swiss pharma at risk of US trade investigation, industry body says

2026-08-14

Swiss Economy Surges Far More Than Forecast, Led by Pharma

Swiss Firms Invest $27 Billion in US After Tariff Deal, NZZ am Sonntag Reports

FAQ